



URKUNDE

Es wird hiermit bescheinigt,
dass für die in der Patentschrift
beschriebene Erfindung ein
europäisches Patent für die in der
Patentschrift bezeichneten Ver-
tragsstaaten erteilt worden ist.

CERTIFICATE

It is hereby certified that a
European patent has been granted
in respect of the invention
described in the patent specifica-
tion for the Contracting States
designated in the specification.

CERTIFICAT

Il est certifié qu'un brevet
européen a été délivré pour
l'invention décrite dans le
fascicule de brevet, pour les
Etats contractants désignés
dans le fascicule de brevet.

Europäisches Patent Nr.

European patent No.

Brevet européen n°

2742065

Patentinhaber

Proprietor of the patent

Titulaire du brevet

E.R.D.E.-aak-Diagnostik GmbH
Biomedizinischer Forschungscampus
Berlin-Buch
Robert-Rössle-Str. 10
13125 Berlin/DE

Max-Delbrück-Centrum für Molekulare Medizin in der
Helmholtz-Gemeinschaft
Robert-Rössle-Strasse 10
13125 Berlin/DE

Benoît Battistelli

Präsident des Europäischen Patentamts
President of the European Patent Office
Président de l'Office européen des brevets

München, den
Munich,
Fait à Munich, le

02.08.17



(11) **EP 2 742 065 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
02.08.2017 Bulletin 2017/31

(51) Int Cl.:
C07K 14/705 (2006.01) A61P 25/28 (2006.01)

(21) Application number: **12743103.9**

(86) International application number:
PCT/EP2012/063789

(22) Date of filing: **13.07.2012**

(87) International publication number:
WO 2013/023852 (21.02.2013 Gazette 2013/08)

(54) **AGONISTIC AUTOANTIBODIES TO THE ALPHA1-ADRENERGIC RECEPTOR AND THE BETA2-ADRENERGIC RECEPTOR IN ALZHEIMER'S AND VASCULAR DEMENTIA**

AGONISTISCHE AUTOANTIKÖRPER GEGEN DEN ALPHA1-ADRENERGEN REZEPTOR UND BETA2-ADRENERGEN REZEPTOR BEI MORBUS ALZHEIMER UND VASKULÄRER DEMENZ

AUTO-ANTICORPS AGONISTES CONTRE LE RÉCEPTEUR ADRÉNERGIQUE ALPHA1 ET LE RÉCEPTEUR ADRÉNERGIQUE BÊTA2 DANS LA DÉMENCE D'ALZHEIMER ET VASCULAIRE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(56) References cited:
**WO-A2-02/09374 WO-A2-02/16431
WO-A2-2005/109000 WO-A2-2009/090227**

(30) Priority: **12.08.2011 EP 11177414**

(43) Date of publication of application:
18.06.2014 Bulletin 2014/25

(73) Proprietors:
• **E.R.D.E.-aak-Diagnostik GmbH
13125 Berlin (DE)**
• **Max-Delbrück-Centrum für Molekulare Medizin in
der
Helmholtz-Gemeinschaft
13125 Berlin (DE)**

(72) Inventors:
• **BIMMLER, Marion
15712 Königs Wusterhausen OT Zernsdorf (DE)**
• **KARCZEWSKI, Peter
13125 Berlin (DE)**
• **HEMPEL, Petra
12621 Berlin (DE)**

(74) Representative: **Hertin und Partner
Rechts- und Patentanwälte PartG mbB
Kurfürstendamm 54/55
10707 Berlin (DE)**

- **KUNZE ET AL: "Agonistic autoantibodies against the alpha1-adrenoceptor in patients with Morbus Alzheimer and vascular dementia", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION, ELSEVIER, NEW YORK, NY, US, vol. 6, no. 4, 1 July 2010 (2010-07-01), page S413, XP027439870, ISSN: 1552-5260, DOI: 10.1016/J.JALZ.2010.05.1390 [retrieved on 2010-07-01]**
- **NI Y ET AL: "Activation of [beta]2-adrenergic receptor stimulates [gamma]-secretase activity and accelerates amyloid plaque formation", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 12, no. 12, 1 January 2006 (2006-01-01), pages 1390-1396, XP009105415, ISSN: 1078-8956, DOI: 10.1038/NM1485 cited in the application**
- **P. KARCZEWSKI ET AL: "Agonistic Autoantibodies to the [alpha]1-Adrenergic Receptor and the [beta]2-Adrenergic Receptor in Alzheimer's and Vascular Dementia", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 75, no. 5, 1 May 2012 (2012-05-01), pages 524-530, XP55041432, ISSN: 0300-9475, DOI: 10.1111/j.1365-3083.2012.02684.x**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 742 065 B1